Novacyt S.A. (NCYT.L) Update on Notice of 2020 Full Year Results

Paris, France and Camberley, UK – 18 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2020 on Tuesday 22 June 2021.

The Company has changed its reporting currency from Euro to Great British Pounds (GBP) for these results, and will report in GBP going forward, as the cost base of the business is now mainly located in the UK and GBP is the largest invoicing currency for sales. The results for the year ended 31 December 2019 will be restated to GBP to provide the same currency comparison.

– End –

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website:

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.